Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Medipattern closes US$5.2 million bought-deal financing

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Research Capital

On August 2, 2007, Medipattern Corporation announced that it had closed its bought deal with Research Capital Corporation. Medipattern issued 4,730,000 common shares at a price of $1.10 per share for aggregate gross proceeds of $5,203,000. On August 17, Research Capital partially exercised an over-allotment option for additional proceeds of $521,290, for aggregate gross proceeds of the offering of $5,724,290. Medipattern is an award-winning developer of computer-aided diagnosis (CAD) medical imaging software designed to detect cancer and permit a higher standard of care for the millions of patients at risk of cancer. Research Capital was advised in this transaction by Rubin Rapuch, Jeffrey Klam, Catherine Fraser, David Turgeon and Leanne Shaughnessy of Fasken Martineau.

Team

    Subscribe

    Receive email updates from our team

    Subscribe